Founders
John Focas (Founder)
John is responsible for overall leadership of the business.
John is a leader and connector, with over 30 years in business. He has successfully established and built various businesses in Australia and globally. He has particular experience in technology and building platforms to support expansion and growth. John brings drive, a vast network and proven track-record of developing high-quality teams.
Martin Morrow-Woods (Co-Founder)
Marty is responsible for Product Design and Research & Development
An industrial designer by trade, Marty has over 25 years’ experience in industry and as a business owner. He has a passion for developing innovative products and systems that allow us to live a better life now and into the future.
The Story
Developed in Queensland, Australia, CLEO2 reflects the shared passion of its founders to improve the quality of people’s lives. The COVID-19 pandemic shone a light on the harms arising from airborne viruses. This was the catalyst for years of Research & Development, culminating in CLEO2.
“We started with a focus on public transport, so our children could get the bus to and from school safely. We soon realised the broader potential and widespread demand. We set out to tailor the device for use in a broad range of settings” John Focas
Advisers
Dr Heike Neumeister-Kemp (Mycologist & Air Quality)
Dr Heike Neumeister-Kemp is CEO and Principal Mycologist (mould and fungus) at Mycolab, Australia’s leading laboratory for Environmental Mycology particularly as it relates to indoor environments.
Heike is a globally renown Mycologist. She has held various roles as a Researcher and teacher at Universities. She regularly acts as an expert witness in major legal matters concerning mould and its health effects, and advises on a range of projects in the space.
Dr Vanessa Zann (Senior Research Scientist)
Vanessa, with 20+ years in biopharmaceutics, holds a BSc in Biology and a PhD in Caco-2 cell dipeptide transport. Formerly at BMS and AstraZeneca, she led the global Caco-2 facility, overseeing NCE selection and providing biopharmaceutics support.
Joining Quotient Sciences in 2012, Vanessa spearheaded Modelling and Simulation implementation, shaped in vitro characterization strategy, designed clinical studies, and played a pivotal role in over 100 clinical Phase 1 studies. As a Senior Drug Development Consultant, she provides industry consultancy and supports business development.
Rohan Singh (GPRS Capital, Strategic Partner)
Rohan has an extensive background in Executive-level roles across the private sector and Government, spanning Strategy, Projects, Risk, Governance, Corporate Affairs & Communications, Chief of Staff and General Counsel. He commenced his career as a Corporate Lawyer at a leading global law firm. Rohan is keenly focused on Strategy, disciplined execution and governance.
George Polydoros (GPRS Capital, Strategic Partner)
George is an Engineer by trade with an extensive track record of building and exiting leading Australian businesses. He supports Strategy, Product Development and systems and processes.